ArticleAllergy2025
HLA-A*02:01 Presents Penicillin-Modified Cysteinylated Peptides for T Cell Recognition.
Article in Allergy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundA subset of patients experience immune-mediated hypersensitivity reactions towards β-lactam antibiotics, with drug-specific T cells implicated as one of the causative factors. The principal mechanism is thought to involve chemical haptenation of self-peptides, resulting in novel peptide drug-adducts that may trigger T cell recognition. Understanding the interactions between the β-lactam drug, the T cell receptor (TCR) and the peptide/human leukocyte antigen (pHLA) complex is critical to gain further mechanistic insights into these hypersensitivity reactions. This study aimed to 1) explore the array of haptenated ligands presented by HLA-A*02:01, 2) evaluate the repertoire of T cells involved in penicillin-induced reactions in a hypersensitive patient and 3) determine if a dominant penicillin-specific TCR clonotype recognises haptenated HLA peptides.
methodAn immunopeptidomics approach was applied to identify benzylpenicillin (BP)-modified peptide ligands within the HLA-A*02:01 ligandome. The drug-reactive TCR repertoire was analysed by single-cell sequencing of CD8
resultWe report that BP modifies cysteine in preference to lysine residues within the HLA-A*02:01 immunopeptidome. This modification occurs via cysteine-drug conjugate formation, in conjunction with disulphide-mediated peptide modification, which has not previously been considered in the context of drug hypersensitivities. Furthermore, we demonstrate that a BP-specific TCR expanded from a patient reacts towards a reduction-sensitive epitope, consistent with a BP-cysteine adduct disulphide linked to a cysteine residue within the T cell epitope.
conclusionOur study provides evidence that cysteine-penicillin adducts can be accommodated by HLA ligands with the potential to induce T cell-mediated allergic reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.